GSK’s Enduring Leadership in Respiratory Care: Shaping the Future for Patients

Respiratory diseases affect millions globally, presenting ongoing challenges for health care systems worldwide. For decades, GSK has been a global leader in respiratory care, driving innovation and improving the lives of patients living with such conditions as asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). In Canada, GSK’s contributions to respiratory and airway disease medicine have been particularly impactful, blending science and patient-focused solutions to advance care. But it takes more than just science: partnerships and a commitment to equity are essential.

A Legacy of Innovation

GSK’s history in respiratory medicine is marked by groundbreaking therapies that have transformed treatment paradigms. From pioneering inhaler technology to introducing biologics that address complex inflammatory pathways, GSK has consistently raised the standard of care.

“The Canadian Thoracic Society acknowledges the long-standing commitment of GSK to research and innovation that has developed important therapies for patients and supported investigator-driven research in respiratory medicine,” comments Erika Penz, MD, president of the Canadian Thoracic Society.

For patients with severe asthma, CRSwNP and comorbidity, innovations are opening new doors to treatment. Such biologic therapies as monoclonal antibodies designed to target specific immune pathways are revolutionizing care by addressing the root causes of diseases rather than just managing symptoms. These advancements are particularly significant for patients with nasal polyps, a condition often associated with chronic sinus inflammation and breathing difficulties.

“Respiratory care is not just about developing medications. It’s about creating solutions that fit seamlessly into patients’ lives while addressing underlying disease mechanisms,” says Dr. Michelle Horn, country medical director for GSK Canada. “At GSK, we work tirelessly to ensure our treatments empower patients to live healthier, fuller lives.”

An enduring partner

Canada plays a vital role in GSK’s global respiratory efforts, contributing to clinical research and patient-centred programs. Collaborations with academic institutions and health care organizations have positioned GSK Canada as a leader in advancing scientific discourse and generating real-world evidence to understand how therapies perform in everyday settings.

Beyond research, GSK aims to foster a collaborative environment that accelerates the development and adoption of innovative solutions. GSK Canada has strengthened its partnerships with advocacy groups and health care providers, focusing on advancing education for both patients and health care practitioners.

As Edmond Chan, MD, FRCPC, president of the Canadian Society of Allergy and Clinical Immunology, indicates, “Collaboration is key to advancing respiratory medicine. We appreciate GSK’s ongoing partnership with professional associations and supportive efforts to improve standards of care and provide better outcomes for patients across Canada.”

Through these initiatives, GSK reinforces its commitment to advancing medical management in complex respiratory conditions, ensuring health care professionals are equipped to deliver the highest standard of care. By combining a strong legacy of innovation with an unwavering focus on education and patient outcomes, GSK continues to set the standard in respiratory and airway care, empowering health care professionals and transforming patients’ lives.

Addressing the challenges of COPD requires a collaborative approach. “COPD Canada appreciates GSK’s commitment to working alongside patient advocacy groups and health care providers to improve the lives of those affected by this chronic condition,” says Henry Roberts, managing director of COPD Canada.

Innovating with Biologic Medicines

In recent years, GSK has expanded its focus to biologic medicines, which represent a new frontier in airway and respiratory care. Biologics are highly targeted therapies designed to address the underlying mechanisms of diseases. These treatments are particularly promising for patients with such conditions as CRSwNP and severe asthma, offering personalized solutions based on the patient’s unique disease profile.

“Biologic medicines are enabling us to provide more precise and effective treatments for patients with complex airway diseases,” explains Dr. Horn. “For patients struggling with chronic nasal polyps and severe asthma, these therapies can make a profound difference, improving disease control and enhancing overall quality of life.”

By precisely targeting immune pathways, such as IL-5 signalling, biologics offer a transformative approach to care for patients who have previously found limited relief. This targeted strategy enables individualized treatments that address both the inflammatory and structural components of diseases like severe asthma and CRSwNP. Building on the success of clinical programs of biologics targeting the IL-5 pathway, there is growing optimism that biologics have the potential to improve patient outcomes in COPD and address unmet needs.

GSK is also committed to addressing health equity in respiratory care. Initiatives are in place to ensure diverse patient populations have access to the latest treatments and support services. “We recognize that not all patients have the same access to care,” notes Dr. Horn. “We’re working with community partners to bridge these gaps and ensure equitable access to our therapies.”

Jeffrey Beach, president and CEO of Asthma Canada, emphasizes the importance of community-based access: “It’s not enough to just have new treatments. We need to make sure they reach everyone who needs them. GSK’s commitment to working with patient community organizations to improve access is crucial for patients who often face systemic barriers.”

The Road Ahead

As airway and respiratory illnesses continue to rise, GSK remains dedicated to pioneering new therapies and exploring emerging areas, like ultra-long-acting biologic treatments and precision medicine. GSK is focused on developing sustainable solutions that benefit both patients and the health care system. This includes initiatives aimed at reducing the environmental impact of respiratory treatments and promoting responsible prescribing practices.

Dr. Horn shares optimism for the future: “The airway disease landscape is evolving, and GSK is proud to lead the charge toward innovative solutions that redefine what’s possible for patients.”

To learn more about GSK Canada and our R&D approach, please visit https://ca.gsk.com/en-ca/innovation/